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BACKGROUND: Major depressive disorder (MDD) is a disabling mood disorder, and despite a known heritable
component, a large meta-analysis of genome-wide association studies revealed no replicable genetic risk variants.
Given prior evidence of heterogeneity by age at onset in MDD, we tested whether genome-wide signiﬁcant risk
variants for MDD could be identiﬁed in cases subdivided by age at onset.
METHODS: Discovery case-control genome-wide association studies were performed where cases were stratiﬁed
using increasing/decreasing age-at-onset cutoffs; signiﬁcant single nucleotide polymorphisms were tested in nine
independent replication samples, giving a total sample of 22,158 cases and 133,749 control subjects for subsetting.
Polygenic score analysis was used to examine whether differences in shared genetic risk exists between earlier and
adult-onset MDD with commonly comorbid disorders of schizophrenia, bipolar disorder, Alzheimer’s disease, and
coronary artery disease.
RESULTS: We identiﬁed one replicated genome-wide signiﬁcant locus associated with adult-onset (.27 years) MDD
(rs7647854, odds ratio: 1.16, 95% conﬁdence interval: 1.11–1.21, p 5 5.2 3 10-11). Using polygenic score analyses, we
show that earlier-onset MDD is genetically more similar to schizophrenia and bipolar disorder than adult-onset MDD.
CONCLUSIONS: We demonstrate that using additional phenotype data previously collected by genetic studies to
tackle phenotypic heterogeneity in MDD can successfully lead to the discovery of genetic risk factor despite
reduced sample size. Furthermore, our results suggest that the genetic susceptibility to MDD differs between
adult- and earlier-onset MDD, with earlier-onset cases having a greater genetic overlap with schizophrenia and
bipolar disorder.
Keywords: Age at onset, GWAS, Heterogeneity, Major depressive disorder, Polygenic scoring, StratiﬁcationISShttp://dx.doi.org/10.1016/j.biopsych.2016.05.010& 2016 Society of Biological Psychiatry. This is an open access article under the
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Genomic Analysis of Age at Onset in Depression
Biological
PsychiatryMajor depressive disorder (MDD) is a highly prevalent and
heterogeneous disorder (1). With most individuals experi-
encing recurrent episodes throughout life (2), MDD is now
the second leading cause of disability worldwide (3). MDD is
deﬁned by low mood and energy, inability to experience
enjoyment, changes to eating and sleep patterns, feelings
of guilt or worthlessness, and suicidal thoughts (4). Along
with excess mortality and increased risk of suicide (5), MDD
is associated with worse clinical outcomes when comorbid
with health problems such as cardiovascular disease and
cancer (6,7). Although the heritability is estimated at 31% to
42% (8), the causal variants remain elusive: a recent large
mega-analysis with over 9000 MDD cases failed to identify
any replicable associations (9), despite successes in sim-
ilarly sized studies of schizophrenia (SCZ) and bipolar
disorder (BPD) (10,11). This lack of biological markers may
be among the causes for the well-established underfund-
ing of research into MDD relative to its economic and
health burden (12) and the reported stigmatization of suffer-
ers (13).
However, several differences exist between MDD and other
psychiatric disorders in which replicable genetic associations
have been identiﬁed, including higher prevalence, greater
diagnostic uncertainty, lower heritability, and, crucially,
increased heterogeneity. One known source of heterogeneity
that may contribute substantially is age at onset (AAO). Onset
can occur at any stage of life, yet many factors associated with
MDD are either age speciﬁc or age restricted. These include
biological events such as puberty, menopause, and dementia,
and environmental risk factors including childhood maltreat-
ment, childbirth, and divorce. Earlier onset is associated with
increased risk in ﬁrst-degree relatives and with higher heritability
(14–18). Considerable differences in the transmission of early-
versus late-onset MDD have also been reported (19,20), with
some studies suggesting the effects of novel genetic risk
factors for MDD appearing later in life (21,22).
Here we build on the previous mega-analysis of the Major
Depressive Disorder Working Group of the Psychiatric
Genomics Consortium (PGC-MDD), using AAO to stratify
cases within a sample of 8920 cases and 9521 control
subjects, with the goal of reducing heterogeneity. For each
of the nine PGC-MDD samples (23–30), cases were ordered by
AAO within study and divided into eight groups (octiles).
Genome-wide association analysis of cases in these octiles
was performed systematically against control subjects for
1,235,109 autosomal single nucleotide polymorphisms (SNPs).
We examined three analytic strategies: 1) genetic variants
speciﬁc to early-onset MDD; 2) risk variants speciﬁc to late-
onset MDD; and 3) restricting to the intermediate four octiles
excluding the 25% of cases at either extreme of AAO to test
for potential heterogeneity introduced from very early or very
late onset. Signiﬁcantly associated SNPs were taken forward
for replication in nine studies comprising 13,238 cases and
124,230 control subjects. We also examined the differences
between early- and late-onset MDD in their shared heritability
with commonly comorbid disorders of schizophrenia, bipolar
disorder, Alzheimer’s disease, and coronary artery disease
to identify differences in genetic etiologies across onset
groups.2 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalMETHODS AND MATERIALS
Description of Samples
Full details of the studies that form the PGC-MDD are given in
the supplementary materials of the original data analysis (9).
Brieﬂy, these nine MDD studies (23–30) conducted genome-
wide genotyping on individual subjects of European ancestry.
Subjects were required to have diagnoses of DSM-IV lifetime
MDD established using structured diagnostic instruments
from direct interviews by trained interviewers or clinician-
administered DSM-IV checklists. Two studies required recur-
rent MDD and one study required recurrent, early-onset MDD.
Studies ascertained cases mostly from clinical sources, and
control subjects were largely randomly selected from the
population and screened for lifetime history of MDD. This led
to a total of 9238 cases and 9521 control subjects with
genotype information.
AAO Phenotype
AAO was deﬁned as the age at which individuals ﬁrst had
symptoms that met the criteria of MDD and was self-reported in
all studies. Of the original 9238 cases included in the sample,
8920 (95.6%) had a reported AAO. Cases reporting an AAO
older than the recorded age at interview were removed from the
analysis (n = 17). Within each study, cases were ordered by
AAO and then divided into octiles, giving approximately 1000
cases per octile. Octiles were deﬁned within each study to
account for differences in case ascertainment. We noted a wide
range in AAO between studies ascertaining recurrent depres-
sion using the same instrument, indicating that the precise
setting (study, clinic, country) was important; we therefore
chose to order cases by AAO within each study, rather than
across studies, or by absolute AAO cutoffs. This strategy will
identify genetic variants that were speciﬁc to early or late onset,
relative to the mean AAO of the recruited cases. For secondary
analysis of sex-speciﬁc effects, octiles were additionally deﬁned
within only male and female subjects for analysis of sex-speciﬁc
effects, and for recurrent depression that has a higher herit-
ability. These octiles will be referred to as O1 to O8, with O1
representing the earliest onset octile and O8 representing the
latest onset octile. The GenRED (Genetics of Recurrent Early-
Onset Depression) study only recruited MDD cases with an
AAO below 31 years (25). We compared the distribution of AAO
in GenRED with other similar studies (STAR*D [Sequenced
Treatment Alternatives to Relieve Depression], RADIANT-UK)
and estimated that GenRED recruited the youngest cases (62%
of all possible MDD cases), with older cases absent from the
study (Supplemental Figure S1). GenRED cases were ordered
by AAO and assigned to the appropriate octiles O1 to O5, with
no cases present in O6 to O8.
Quality Control
Genotyping was described in the supplementary materials in
the original analysis (11). All samples were genotyped with
SNP arrays of at least 200,000 SNPs. SNPs were removed for
missingness .0.02, case-control difference in SNP missing-
ness .0.02, SNP frequency difference from HapMap3 (phase
three of the International HapMap Project) .0.15, or deviation
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p , 1.0 3 10–6). Subjects were removed for excessive
missingness (.0.02), for being identical or closely related to
any subject in any sample (p̂ . .2 based on common
autosomal SNPs), or if there was evidence for diverging
ancestry. Ancestry was estimated using multidimensional
scaling applied to 8549 SNPs directly genotyped in all
samples and in approximate linkage equilibrium. Imputation
was performed using Beagle 3.0.440 (31) with the CEU
HapMap3 data (32) to impute 1,235,109 autosomal SNP
allele dosages. The ﬁrst 20 ancestry-informative principal
components were included as covariates, along with an
indicator for each study.
Genome-wide Association Analysis
Genome-wide association analysis was performed in PLINK
using logistic regression to test the association between case-
control phenotype and imputed SNP dosages under an
additive model (33). Genotyping coordinates are given in NCBI
Build 36/UCSC hg18 (National Center for Biotechnology
Information, Bethesda, MD). Quality control was conducted
separately for each sample. To test for SNPs associated with
distinct aspects of MDD based on AAO, we performed three
hypothesis-driven analyses (Supplemental Figure S2). The ﬁrst
analysis targeted those SNPs associated with early-onset
MDD in a series of genome-wide association analyses, initially
looking at the earliest onset cases (O1) against all control
subjects, then the combined O1 and O2 cases against control
subjects, then O1 to O3, etc., until all cases were included.
This approach was based on the sequential additions method
(34), which was developed to account for a quantitative trait
that is measured in cases but not control subjects and provide
an estimate of the best phenotype deﬁnition for future studies.
The second analysis was similarly performed to examine those
SNPs associated with later-onset MDD, but reversing the
procedure (i.e., ﬁrst looking at the latest-onset cases [O8]
against all control subjects, then O7–O8 against control
subjects, then O6–O8, etc., until all cases were included).
The third analysis tested whether the extremes of AAO, both
early and late, were introducing heterogeneity to the cases
excluding O1 to O2 and O7 to O8, leaving those cases with
onset within the interquartile range of AAO for each study (O3–
O6). We then tested O3 to O6 cases against all control
subjects. Each analysis was performed using all cases, male
cases only, female cases only, and recurrent cases only.
Analyses of all, or almost all, cases (O1–O8, O1–O7, or O2–
O8) were used to identify SNPs that reached greatest signiﬁ-
cance without an AAO-speciﬁc effect and so were omitted
from further analysis as would have been captured in the
primary analysis of this data. In total, 52 genome-wide
analyses were performed [5 (6 1 6 1 1) 3 4], making the
standard multiple testing threshold of p , 5.0 3 10–8 for
genome-wide signiﬁcance anticonservative. We applied a
Bonferroni correction for 52 analyses to genome-wide signiﬁ-
cance, which is highly conservative because many analyses
were highly correlated. For replication, we selected SNPs with
p , 9.5 3 10–10 in the discovery sample in more than one
analysis (either by sex or recurrence or inclusion of octiles); the
combination of cases that yielded the greatest signiﬁcancewas chosen as the basis for replication. This analysis strategy
uses AAO as a stratifying variable to construct subsets of cases
that may be more homogeneous and identify SNPs that are
associated with susceptibility to MDD with a restricted AAO;
it does not identify SNPs that control MDD AAO, which would
require a case-only analysis of AAO as a quantitative trait.
Replication Analysis
Five replication samples used in the primary analysis of this
dataset had AAO information available [TwinGene (35), GenREDII/
DepGenesNetwork (25), deCODE (9), PsychCoLaus (36), SHIP-
LEGEND (Study of Health in Pomerania–Life-Events and Gene-
Environment Interaction in Depression) (37)]. The GenPod/NEW-
MEDS and Harvard i2b2 studies, which appeared in the repli-
cation of the primary analysis of this dataset, did not have AAO
data available and were not included. Four new replication studies
were available: 1) a collection of samples available through the
University of Münster (38,39); 2) a combination of RADIANT cases
from Denmark (40), the Danish DEMO and PRISME studies of
MDD (41,42), and a set of Danish population control subjects; 3)
the CONVERGE (China Oxford and VCU Experimental Research
on Genetic Epidemiology) study of MDD cases and control
subjects recruited in China (18,43,44); and 4) the Generation
Scotland study, which included measures on MDD (45). These are
outlined, alongside the deﬁnitions of AAO, in Supplemental
Methods. Due to the early median AAO in the GenREDII/
DepGenesNetwork, an artiﬁcial “median” was introduced at age
27 years, based on the median for the discovery samples. Those
SNPs that passed our threshold of p , 9.5 3 10–10 in the
discovery sample were tested for association within these nine
replication studies. Due to differences in availability of genome-
wide genotype data, each study was genotyped and/or imputed
separately. A ﬁxed-effect inverse variance based meta-analysis of
the replication studies was performed using METAL (46).
Polygenic Analysis
We also examined the association between early- and late-onset
MDD and polygenic risk scores for other psychiatric disorders, as
this might reﬂect either shared genetic etiology or phenotypic
contamination (47). Polygenic risk scores for schizophrenia (9379
cases and 7736 control subjects) and bipolar disorder (6990
cases and 4820 control subjects) were created by the PGC,
using imputed data and removing overlapping control subjects,
ensuring that the datasets were completely independent (10,11).
Alzheimer’s disease polygenic risk scores were obtained from
the GERAD (Genetic and Environmental Risk for Alzheimer’s
disease) Consortium (48) and the coronary artery disease scores
from the CARDIoGRAM Consortium (49). The imputed GERAD
sample comprised 3177 cases and 7277 control subjects, and
the CARDIoGRAM consortium consisted of 22,233 cases and
64,762 control subjects. All four disorders were chosen for their
previous genetic and epidemiological evidence of overlap with
MDD (50–52).
Polygenic risk scores were calculated for MDD cases and
control subjects, summing the number of risk alleles carried,
weighted by the natural log of their odds ratio in the original
genome-wide association study (GWAS). Score SNPs with low
minor allele frequency (,0.02) or in the major histocompati-
bility complex region were removed, and score datasets wereBiological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 3
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mand in PLINK to remove SNPs within 500 kb and
r2 . .25 with a more signiﬁcantly associated SNP. Seven
scores were calculated, using a p value threshold (PT) to
restrict to the most signiﬁcant SNPs in their original genome-
wide association analysis (PT , .01, .05, .1, .2, .3, .4, .5).
Logistic regression was used to test for association between
polygenic risk scores and case-control status using four
different case-control sets (all MDD cases vs. control subjects,
O1–O3 cases vs. control subjects, O6–O8 cases vs. control
subjects, and O1–O3 cases vs. O6–O8 cases) with 20 population
principal components and study indicators as covariates. We
calculated the proportion of variance explained (Nagelkerkeʼs R2)
by subtraction of a full model (covariates 1 polygenic risk
score) from a reduced model (covariates only). The GenRED
sample was not included in the analysis as they had no cases
within the O6–O8 analysis; the Bonn-Mannheim study was not
included in the analysis of Alzheimer’s disease or coronary artery
disease due to overlapping control subjects with the respective
consortia.RESULTS
Summary of AAO
After quality control, the sample consisted of 8920 MDD cases
with AAO information and 9519 control subjects with
1,235,109 SNPs. The median AAO across all cases excluding
GenRED was 27 years old (interquartile range: 18, 38) and the
mean 28.9 613.64, reﬂecting the long tail of older onset cases
(Figure 1 and Supplemental Figure S3). Median AAO by study
ranged from 20 to 37 years (16 for GenRED, which recruited
only recurrent cases with onset no greater than 30), with the
German samples having a slightly older onset. Mean AAO wasFigure 1. Distribution of age at onset across the nine studies included in
the discovery analysis. Mid-gray band shows interquartile range across all
studies excluding GenRED (Genetics of Recurrent Early-Onset Depression),
which recruited only cases onset at 30 years or less. GAIN, Genetic
Association Information Network; GSK, GlaxoSmithKline; MPIP, Max Planck
Institute of Psychiatry; NESDA, Netherlands Study of Depression and
Anxiety; NTR, Netherlands Twin Register.
4 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journallower for recurrent than nonrecurrent cases, 27.1 to 33.0 (p ,
.001, correcting for study and excluding GenRED). AAO was
also older for male subjects with a mean of 29.0 compared
with 26.7 in female subjects (p , .001).
Genome-wide Association Analysis
Our analysis of both early- and late-onset octiles and the
intermediate median of AAO excluding extreme-AAO cases led
to four tests passing our signiﬁcance cutoff for replication (p ,
9.5 3 10–10), all for associations with SNP rs7647854 on
chromosome 3. The only genome-wide signiﬁcant association
for this SNP was in the 50% oldest onset cases against all
control subjects (O5–O8: p5 3.4 3 10-11) (Supplemental Figures
S4 and S5). As a secondary analysis of this SNP, we split cases
within our discovery sample into nonoverlapping quartiles and
analyzed them against control subjects. This showed a strong
association in the oldest quartile (O7–O8: p 5 9.0 3 10–10, odds
ratio [OR]: 1.37, 95% conﬁdence interval [CI]: 1.23–1.51)
(Figure 2), a moderate effect in the third quartile (O5–O6: p 5
2.0 3 10–5, OR: 1.23), and no evidence of association in the two
youngest quartiles (O1-O2: p 5 .07, OR: 1.09; O3-O4: p 5 .30,
OR: 1.06). Furthermore, when the inclusion threshold for AAO
was increased 1 year at a time within each study (until only 100
cases remained), we observed a gradual increase in effect size
for rs7647854 in all studies as the analysis was restricted to
progressively later onset cases (Supplemental Figure S6). Anal-
ysis by sex or recurrence revealed no additional ﬁndings.
Replication Analysis
Given the results from our discovery dataset, rs7647854 was
taken forward for replication in nine independent studies
(Table 1). The SNP was tested for association with oldest half
of MDD cases (O5–O8), because this analysis attained the
smallest p value in the discovery studies. The SNP was either
directly genotyped or imputed at high conﬁdence across all
studies (Supplemental Table S1). The SNP was signiﬁcantly
associated with MDD in a meta-analysis of these studies,
with a p value of 7.5 3 10–4 and an OR of 1.10 (total number
of MDD cases 5 6107 and total number of control subjects
124,230) (Table 2; Supplemental Figure S5). Meta-analysis of
the combined discovery sample with individual replica-
tion studies gave a p value of 5.2 3 10–11 and an OR of 1.16
(95% CI: 1.11–1.21), surpassing genome-wide signiﬁcance.
Polygenic Analysis of Comorbid Illnesses
In the PGC-MDD discovery studies, polygenic risk scores for
BPD and SCZ were signiﬁcantly associated with early-onset
MDD. Restricting to only early-onset cases (O1-O3) versus
control subjects, the amount of phenotypic variability explained
(BPD: R2 5 .41%, p 5 1.4 3 10–12; SCZ: R2 5 .67%, p 5 3.0
3 10–19) was much greater than for later onset (O6–O8) cases
(BPD: R2 5 .16%, p 5 1.9 3 10–5; SCZ: R2 5 .14%, p 5 3.9
3 10–5) (Figure 3). A similar increase in association with late-
onset comorbid disorders was not seen. Polygenic risk scores
for coronary artery disease from the CARDIoGRAM Consortium
(49) were weakly positively associated with MDD, but this was
consistent across early and late onset cases, in contrast to BPD
and SCZ (coronary artery disease: O1–O3 cases vs. control
subjects, R2 5 .05%, p 5 .01; O6–O8 cases vs. control
Figure 2. Evidence for association
and effect size for rs7647854 on
chromosome 3, with cases split into
nonoverlapping quartiles by age at
onset within discovery studies. O,
octile.
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R2 # .01%, p 5 .76) (Figure 3). No association with MDD status
was seen for the scores generated for Alzheimer’s disease from
the GERAD Consortium (48) regardless of AAO (O1–O3 casesTable 1. Summary of MDD Discovery and Replication Cohorts
Study Country Measu
Discovery NESDA/NTR (GAIN) The Netherlands CIDI
GenRED United States DIGS3
GSK Germany SCAN
MDD2000-QIMR_610 Australia CIDI/SS
MDD2000-QIMR_317 Australia CIDI/SS
MPIP Germany Asked a
RADIANT Bonn/Mannheim Germany SCAN
RADIANT United Kingdom SCAN
STAR*D United States Asked a
Total
Replication TwinGene Sweden SALT
PsyCoLaus Switzerland DIGS
SHIP-LEGEND Germany M-CIDI
GenRED2/DepGenesNetworks United States DIGS3
University of Münster Germany SCID
Combined Danish sample Denmark SCAN
CONVERGE China
deCODE Iceland Hospita
Generation Scotland United Kingdom SCID
Total
Total
AAO, age at onset; CONVERGE, China Oxford and VCU Experimenta
Diagnostic Interview; DIGS, Diagnostic Interview for Genetic Studies; GA
Recurrent Early-Onset Depression; GSK, GlaxoSmithKline; M-CIDI, Munich
disorder; MPIP, Max Planck Institute of Psychiatry; NESDA, Netherlands Stu
Screening Across the Lifespan Twin; SCAN, Schedules for Clinical Assess
Disorders; SHIP-LEGEND, Study of Health in Pomerania–Life-Events and G
Assessment for the Genetics of Alcoholism; STAR*D, Sequenced Treatmenvs. control subjects, R2 , .01%, p 5 .868; O6–O8 cases vs.
control subjects, R25 .02%, p5 .223; O1–O3 cases vs. O6–O8
cases, R2 5 .03%, p 5 .157) (Figure 3). Full results from these
analyses are available in Supplemental Tables S2 and S3.re of AAO Cases With AAO Control Subjects Median AAO
1675 1765 25
1020 1253 16
887 864 36
AGA 432 751 26
AGA 1015 960 26
t interview 373 537 37
883 1290 33
1407 1588 20
t interview 1228 511 21
8920 9519
1009 8601 40
1358 1687 33
381 1827 37
1296 930 17
402 516 27
461 1197 31
5715 5537 34
l records 1005 99,175 39
1611 4760 30
13,238 124,230
22,158 133,749
l Research on Genetic Epidemiology; CIDI, Composite International
IN, Genetic Association Information Network; GenRED, Genetics of
-Composite International Diagnostic Interview; MDD, major depressive
dy of Depression and Anxiety; NTR, Netherlands Twin Register; SALT,
ment in Neuropsychiatry; SCID, Structured Clinical Interview for DSM
ene-Environment Interaction in Depression; SSAGA, Semi-Structured
t Alternatives to Relieve Depression.
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Table 2. Summary of Association With rs7647854, Located
at 3q27.2 (186359477 Base Pairs), With Odds Ratio for the
Reference Allele, G (Frequency 0.16) Compared With the
Nonreference Allele A
Study
MDD
Cases, n
Control
Subjects, n OR (95% CI) p Value
Discovery 3869 9519 1.30 (1.20–1.40) 3.4 3 10–11
Replication 6107 124,230 1.10 (1.05–1.17) 7.5 3 10–4
Meta-analysis 9976 133,749 1.16 (1.11–1.21) 5.2 3 10–11
All results reported are for the oldest half of MDD cases (O5-8), which
had the strongest evidence for association in the discovery study.
CI, conﬁdence interval; MDD, major depressive disorder; OR, odds ratio.
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Our analysis of AAO and the genetic architecture of MDD
suggested that AAO-speciﬁc genetic risk factors exist. Unex-
pectedly, the strongest associations we observed were with
the oldest half of MDD cases, where previous analyses have
focused on early-onset MDD, supported by studies of the
genetic epidemiology of MDD. We emphasize that here “late”-
onset MDD was at still a relatively young age (median onset of
MDD was at age 27 years with 98% of our sample having
onset before 60 years) rather than onset in old age. It is clearer
to conceptualize later-onset cases here as “adult-onset”
cases, and we recommend that this subgroup should be
included in recruitment of future genetic studies, especially
as no difference in the heritability captured by SNPs was
observed for this subtype compared with early-onset cases
(see Supplemental Table S3). However, substantial differences
in AAO across studies make it difﬁcult to put a precise age
cutoff for this recommended adult-onset MDD.
We show signiﬁcant association with rs7647854 on chromo-
some 3, which was associated with the 50% latest-onset cases
(OR: 1.16, p 5 5.2 x 10–11). This SNP was identiﬁed as the
second strongest association in the primary mega-analysis of
the PGC-MDD dataset (9), though at a much lower signiﬁcance,
and did not replicate (discovery p 5 6.5 3 10–7, replication
p 5 .67). Stratifying by AAO leads to much stronger associations
in both the discovery and replication samples, despite the
reduced sample size. Although analyzing across multiple over-
lapping AAO subtypes runs the risk of overﬁtting to maximize
signiﬁcance, we observed highly signiﬁcant associations for this
SNP in both discovery and replication samples. Furthermore, we
also observed a gradual increase in effect size as both raw AAO
within studies and AAO percentile across studies increased
(Figure 2, Supplemental Figure S4). That this was seen both
for raw AAO within studies and as a percentile, and in both
European and Chinese ancestry studies across a wide variety of
AAO measurement tools, suggests that whereas our cutoff of the
50% latest onset cases is arbitrary, the effect exists regardless of
exact cutoff used. However, this does not rule out the possibility
that AAO may be a proxy for a more homogenous subgroup of
MDD based on another factor (e.g., an age-speciﬁc environ-
mental trigger or distinct pattern of symptoms with onset later in
life). That median AAO and effect size across studies was not
signiﬁcantly correlated (r 5 .011, p 5.68) despite greater effect
sizes by AAO percentile within studies suggests that differences
in measurement of AAO across studies might obscure effects.6 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalrs7647854 is intergenic, with ﬂanking genes including C3orf70,
VPS8, EHHADH, and MAP3K13. C3orf70, VPS8, and MAP3K13
all show evidence of expression in the brain in several areas of
potential interest for MDD including the hypothalamus, frontal
cortex, pituitary, and thyroid (GTEx; http://www.gtexportal.org/)
(53). VPS8 and MAP3K13 also show a slight increase in RNA
expression within various brain regions during neonatal develop-
ment (Human Brain Transcriptome; http://hbatlas.org/) (54) with
maintained expression into adulthood.
This genetic association arises with the supposedly less
heritable form of adult-onset MDD, although such summary
measures give no information on the effect sizes of individual
SNPs. One potential explanation is greater contamination of
early-onset MDD cases by individuals misclassiﬁed with MDD
or having comorbid disorders. Longitudinal studies show that
early-onset depressive symptoms predict not only adult
depression but also psychosis [e.g., (55)], and there is signiﬁ-
cant genetic overlap between MDD and other psychiatric
disorders (50). Inclusion of early-onset cases with individuals
who will later develop SCZ or BPD would reduce the power of
GWASs for MDD, though secondary analysis of age at interview
did not support this (Supplemental Figure S7). The polygenic
risk score results show that early- and adult-onset MDD cases
differ in their genetic susceptibility to BPD and SCZ and
suggest that some of the heterogeneity in MDD results from
the inclusion of early-onset cases with a greater genetic overlap
or misclassiﬁcation with these disorders. We did not observe a
similar pattern of association for two disorders that are often
comorbid with late-onset MDD, Alzheimer’s disease, and
coronary artery disease (51,52). We did, however, show for
the ﬁrst time a genetic overlap between MDD and coronary
artery disease irrespective of AAO but no overlap between MDD
and Alzheimer’s disease. We also found that the heritability
explained by SNPs across the genome for early- and late-onset
MDD did not signiﬁcantly differ, suggesting, for common
variants at least, that recruiting only early-onset cases would
not increase power (Supplemental Table S3).
The limitations of our approach are the reduced sample size
and multiple testing from stratifying cases into subtypes, and
requiring potentially less reliable secondary phenotypes to be
widely collected. Measures such as AAO rely on self-report
and are often assessed differently across studies, which can
be problematic for comparison. The analyses presented here
addressed this by analyzing AAO relative to the median of a
study, though this assumed that each study recruited cases
from the same distribution of onset with observed differences
due to how AAO was deﬁned. Furthermore, the effect of our
genome-wide associated SNP were consistent in the replica-
tion studies, ethnicities, and countries, suggesting that differ-
ences in measurement may not be as much of a limitation as
expected, at least in the case of AAO in MDD. The other
disadvantage of looking at more homogenous groups is the
reduction in sample size. However, it has previously been
shown that only modest increases in effect size may be
required to offset the reduction in power from analyzing fewer
cases, implying that analyses of more homogenous subgroups
have the potential to identify novel associations (56).
Our study illustrates the value of using additional pheno-
typic information on cases in GWASs. We show here that
including information on AAO increases the power to detect
Figure 3. Polygenic risk proﬁle scoring analysis of bipolar disorder, schizophrenia, Alzheimer’s disease, and coronary artery disease within the major
depressive disorder (MDD) discovery studies (excluding GenRED [Genetics of Recurrent Early-Onset Depression]). We calculated the proportion of variance
explained (Nagelkerkeʼs R2) by subtraction of a full model (covariates 1 polygenic risk score) from a reduced model (covariates only). AAO, age at onset; O,
octile; PGC, Psychiatric Genomics Consortium.
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Psychiatryassociations with MDD, and that analyzing polygenic risk
scores from related diseases enables us to identify sources
of phenotypic heterogeneity that may have hampered previous
genetic studies. In contrast to other approaches that weight
cases on AAO (57), our stratiﬁcation of cases on AAO is
agnostic to the direction of the phenotypic effect. Our
approach uses the additional phenotype data previously
collected by genetic studies and complements an alternative
emphasis on collecting large sample sizes through minimal
phenotyping. Both strategies will undoubtedly be necessary to
identify and characterize different components of the genetic
architecture of psychiatric disorders. Furthermore, our analysis
shows that tackling phenotypic heterogeneity in MDD can
successfully lead to the discovery of a genetic risk factor
despite reduced sample size. The identiﬁcation here of a novel
genetic risk variant for MDD is of great importance due to both
the scarcity of evidence for the underlying biology and its
pressing economic health burden.ACKNOWLEDGMENTS AND DISCLOSURES
The PGC was funded by National Institute of Mental Health (NIMH) Grant Nos.
MH085520 (to PFS) and MH080403. Statistical analyses were carried out on
the Genetic Cluster Computer (http://www.geneticcluster.org) hosted by
SURFsara and ﬁnancially supported by the Netherlands Scientiﬁc Organiza-
tion Grant No. NWO 480-05-003 (to D. Posthuma) and the department of
Psychology, Vrije Universiteit Amsterdam along with a supplement from the
Dutch Brain Foundation. The Bonn/Mannheim GWAS was supported by the
German Federal Ministry of Education and Research (BMBF) through the
Integrated Genome Research Network Systematic Investigation of the
Molecular Causes of Major Mood Disorders and Schizophrenia Grant Nos.
01GS08144 and 01GS08147, under the auspices of the National Genome
Research Network plus, and through the Integrated Network Integrated
Understanding of Causes and Mechanisms in Mental Disorders, under the
auspices of the e:Med Programme Grant Nos. 01ZX1314A and 01ZX1314G.
The Bonn/Mannheim GWAS was also supported by the German Research
Foundation (DFG) Grant Nos. FOR2107, RI908/11-1, and NO246/10-1. The
GenRED GWAS project was supported by NIMH R01 Grant Nos. MH061686
(to DFL), MH059542 (to W.H. Coryell), MH075131 (W.B. Lawson), MH059552
(JBP), MH059541 (W.A. Scheftner), and MH060912 (MMW). Max Planck
Institute of Psychiatry MARS study was supported by the BMBF Program
Molecular Diagnostics: Validation of Biomarkers for Diagnosis and Outcome
in Major Depression by Grant No. 01ES0811. Genotyping was supported by
the Bavarian Ministry of Commerce, and the BMBF in the framework of the
National Genome Research Network by Grant Nos. NGFN2 and NGFN-Plus,
FKZ 01GS0481 and 01GS08145. The Netherlands Study of Depression and
Anxiety and the Netherlands Twin Register contributed to Genetic Association
Information Network (GAIN)-MDD and to MDD2000. Funding for NTR/NESDA
was from the following: the Netherlands Organization for Scientiﬁc Research
(MagW/ZonMW Grant Nos. 904-61-090, 985-10- 002, 904-61-193, 480-04-
004, 400-05-717, 912-100-20; Spinozapremie Grant No. 56-464-14192;
Geestkracht program Grant No. 10-000-1002); the Center for Medical
Systems Biology (NWO Genomics), Biobanking and Biomolecular Resources
Research Infrastructure, Vrije Universiteit’s Institutes for Health and Care
Research and Neuroscience Campus Amsterdam, BIC/BioAssist/RK (Grant
No. 2008.024); the European Science Foundation (Grant No. EU/QLRT-2001-
01254); the European Community’s Seventh Framework Program (Grant No.
FP7/2007-2013); ENGAGE (Grant No. HEALTH-F4-2007-201413); and the
European Science Council (Grant No. ERC 230374). Genotyping was funded
in part by the GAIN of the Foundation for the US National Institutes of Health,
and analysis was supported by grants from GAIN and the NIMH (Grant No.
MH081802). Funding for the QIMR samples was provided by the Australian
National Health and Medical Research Council (Grant Nos. 241944, 339462,
389927, 389875, 389891, 389892, 389938, 442915, 442981, 496675, 496739,
552485, 552498, 613602, 613608, 613674, 619667), the Australian Research
Council (Grant Nos. FT0991360, FT0991022), the FP-5 GenomEUtwin Project8 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal(Grant No. QLG2-CT-2002-01254), and the US National Institutes of
Health (Grant Nos. AA07535, AA10248, AA13320, AA13321, AA13326,
AA14041, MH66206, DA12854, DA019951), and the Center for Inherited
Disease Research (Baltimore, MD). RADIANT was funded by the following:
a joint grant from the UK Medical Research Council and GlaxoSmithKline
(Grant No. G0701420); the National Institute for Health Research Specialist
Biomedical Research Centre for Mental Health at the South London and
Maudsley National Health Service Foundation Trust and the Institute of
Psychiatry, King’s College London; the UK Medical Research Council
(Grant No. G0000647), and the Marie Curie Industry-Academia Partnership
and Pathways (Grant No. 286213). The GENDEP study was funded by a
European Commission Framework 6 grant (EC Contract Ref.: LSHB-CT-
2003-503428). Genotyping of STAR*D was supported by NIMH Grant No.
MH072802 (to SPH). STAR*D was funded by NIMH Grant No.
N01MH90003 to the University of Texas Southwestern Medical Center
at Dallas (to A.J. Rush). The CoLaus/PsyCoLaus study was supported by
research grants from GlaxoSmithKline, the Faculty of Biology and Med-
icine of Lausanne, and the Swiss National Science Foundation (Grant Nos.
3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468,
33CS30-148401) and two grants from GlaxoSmithKline Clinical Genetics.
SHIP is part of the Community Medicine Research net of the University of
Greifswald, Germany, which is funded by the Federal Ministry of Education
and Research (Grant Nos. 01ZZ9603, 01ZZ0103, 01ZZ0403), the Ministry
of Cultural Affairs, and the Social Ministry of the Federal State of
Mecklenburg–West Pomerania. Genome-wide data have been supported
by the Federal Ministry of Education and Research (Grant No. 03ZIK012)
and a joint grant from Siemens Healthcare, Erlangen, Germany, and the
Federal State of Mecklenburg–West Pomerania. SHIP-LEGEND is funded
by the DFG (Grant No. GR 1912/5-1). The TwinGene study was supported
by the Swedish Ministry for Higher Education, the Swedish Research
Council (Grant No. M-2005-1112), GenomEUtwin (Grant Nos. EU/QLRT-
2001-01254, QLG2-CT-2002-01254), the Swedish Foundation for Strate-
gic Research and the US National Institutes of Health (Grant No. U01
DK066134). The collection of PRISME control subjects and genotyping of
the 883 Danish control subjects was supported by grants from The Danish
Strategic Research Council, The Stanley Research Foundation, and H.
Lundbeck A/S. The Muenster Depression cohorts were supported by the
European Union (Grant No. N Health-F2-2008-222963) and by grants from
the DFG (Grant Nos. FOR 2107 and DA1151/5-1 [to UD]), Innovative
Medizinische Forschung of the Medical Faculty of Münster (Grant Nos.
DA120903, DA111107, and DA211012 [all to UD]). Generation Scotland is
supported by a Wellcome Trust Strategic Award “Stratifying Resilience
and Depression Longitudinally” (Reference No.: 104036/Z/14/Z) and core
support from the Chief Scientist Ofﬁce of the Scottish Government Health
Directorates (Grant No. CZD/16/6) and the Scottish Funding Council
(Grant No. HR03006).
The NIMH Cell Repository at Rutgers University and the NIMH Center for
Collaborative Genetic Studies on Mental Disorders made essential contri-
butions to this project. Genotyping was carried out by the Broad Institute
Center for Genotyping and Analysis with support from Grant No. U54
RR020278 (which partially subsidized the genotyping of the GenRED
cases). Collection and quality control analyses of the control dataset were
supported by grants from NIMH and the National Alliance for Research on
Schizophrenia and Depression.
We acknowledge the contributions of Dr. George S Zubenko and Dr.
Wendy N Zubenko, Department of Psychiatry, University of Pittsburgh
School of Medicine, to the GenRED I project. We are grateful to Knowledge
Networks (Menlo Park, CA) for assistance in collecting the control dataset.
We express our profound appreciation to the families who participated in
this project, and to the many clinicians who facilitated the referral of
participants to the study. We thank the twins and their families registered at
the Australian Twin Registry for their participation in the many studies that
have contributed to this research. We thank V. Mooser, G. Weaber, and P.
Vollenweider who initiated the CoLaus project. We express our gratitude to
the Lausanne inhabitants who volunteered to participate in the PsyCoLaus
study. We would like to acknowledge the PRISME-study group, Denmark,
for collection of the PRISME samples. We thank David M. Hougaard,
Section of Neonatal Screening and Hormones, Statens Serum Institute,
Copenhagen, Denmark; Preben Bo Mortensen, National Centre for
Register-based Research, Aarhus University, Denmark; Merete Nordentoft,
Genomic Analysis of Age at Onset in Depression
Biological
PsychiatryMental Health Centre, Copenhagen, Denmark; and The Lundbeck Founda-
tion Initiative for Integrative Psychiatric Research, iPSYCH, Denmark.
Funding from the BBSRC and MRC is gratefully acknowledged.
Data used in the preparation of this article were obtained from the
Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Con-
sortium. As such, the investigators within the GERAD1 consortia contrib-
uted to the design and implementation of GERAD1 and/or provided data but
did not participate in analysis or writing of this report.
SS, HS, KS, and TET are employees of deCODE Genetics/Amgen. VA
received funds from the German Federal Ministry of Education and
Research, from the European Union (FP 7), and from the Interdisciplinary
Center for Clinical Research Münster, and he has served on the advisory
boards of, or has given presentations on behalf of the following companies:
Astra-Zeneca, Janssen-Organon, Lilly, Lundbeck, Servier, Pﬁzer, Otsuka,
and Trommsdorff. BTB has received funding from the National Health and
Medical Research Council Australia and honoraria from Lundbeck, Bristol-
Meyers Squibb, Sanoﬁ, Servier, Astra-Zeneca, Pﬁzer. IJD is supported by
the MRC-BBSRC, Centre for Cognitive Ageing and Cognitive Epidemiology,
part of the cross council Lifelong Health and Wellbeing Initiative (Grant No.
MR/K026992/1). HJG has received funding from German Research Foun-
dation and Federal Ministry of Education and Research Germany and
speakers honoraria from Eli Lilly and Servier. CH acknowledges support
from the Medical Research Council (MRC) and the Biotechnology and
Biological Sciences Research Council (BBSRC). DJM is supported by an
NRS Career Fellowship, funded by the Chief Scientist Ofﬁce. AMM is
supported by a Scottish Funding Council Senior Clinical Fellowship and by
the Dame Theresa and Mortimer Sackler Foundation and has received
research support from Pﬁzer, Janssen, and Lilly. CMM was supported by
the Netherlands Organization for Scientiﬁc Research (Grant No. NOW VENI
916-76-125). BM-M has consulted for Affectis Pharmaceuticals. MP has
served on the advisory boards of Lundbeck and Eli Lilly.
All other authors report no biomedical ﬁnancial interests or potential
conﬂicts of interest.ARTICLE INFORMATION
From the Institute of Psychiatry, Psychology, and Neuroscience (RAP, IWC,
MR, GB, CML), King’s College London, London; Medical Research Council
Centre for Neuropsychiatric Genetics and Genomics (KET, NC, MJO),
Institute of Psychological Medicine and Clinical Neurosciences, School of
Medicine, Cardiff University, Cardiff, United Kingdom; Lundbeck Founda-
tion Initiative for Integrative Psychiatric Research (HNB, DAB, JG, OM),
iPSYCH; Translational Neuropsychiatry Unit (HNB), Department of Clinical
Medicine, Aarhus University, Aarhus, Denmark; Discipline of Psychiatry (SC-
W, BTB), School of Medicine, University of Adelaide, Adelaide, Australia;
Department of Psychiatry (TB), Virginia Institute for Psychiatric and Behav-
ioral Genetics, Virginia Commonwealth University, Richmond, Virginia;
Division of Psychiatry (LSH, DJM, AMM), University of Edinburgh, Edin-
burgh, United Kingdom; Institute of Social and Preventive Medicine (ZK),
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Queens-
land Brain Institute (SHL, NRW, EMB), The University of Queensland,
Brisbane, Queensland; School of Environmental and Rural Science (SHL),
University of New England, Armidale, New South Wales, Australia; Stanley
Center for Psychiatric Research (SR), Broad Institute of Massachusetts
Institute of Technology and Harvard, Cambridge; Analytic and Translational
Genetics Unit (SR), Massachusetts General Hospital and Harvard Medical
School, Boston, Massachusetts; Department of Psychiatry and Psycho-
therapy (SR), Charité, Campus Mitte, Berlin, Germany; deCODE Genetics
(SS, HS, KS, TET), Reykjavik, Iceland; Institute for Community Medicine
(AT), University Medicine Greifswald, Greifswald, Germany; Department of
Medical Epidemiology and Biostatistics (AV, MLand, PL, PKEM, PFS),
Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry and
Psychotherapy (VA, UD), University of Muenster, Muenster, Germany;
Department of Biological Psychology (DIB, JJH, CMM), EMGO Institute
for Health and Care Research and Neuroscience Campus Amsterdam, Vrije
Universiteit, Amsterdam, The Netherlands; Department of Biomedicine and
Centre for Integrative Sequencing (DAB, JG), iSEQ, Aarhus University,
Aarhus, Denmark; Department of Psychiatry (EC, MP), Lausanne University
Hospital, Lausanne, Switzerland; Department of Psychiatry (UD), Universityof Marburg, Marburg, Germany; Centre for Cognitive Ageing and Cognitive
Epidemiology (IJD, AMM, PT); Department of Psychology (IJD), University of
Edinburgh, Edinburgh, United Kingdom; Institute of Human Genetics (FD,
AJF); Department of Genomics (FD, AJF), Life and Brain Center, University
of Bonn, Bonn, Germany; QIMR Berghofer Medical Research Institute (SDG,
NGM, GWM), Brisbane, Queensland, Australia; Department of Psychiatry
and Psychotherapy (HJG, SVdA), University Medicine Greifswald, Greifs-
wald, Germany; Department of Psychiatry (SPH), Kaiser Permanente San
Francisco Medical Center, San Francisco, California; Medical Genetics
Section (CH, DJP, PT), Centre for Genomic and Experimental Medicine,
Institute of Genetics and Molecular Medicine, University of Edinburgh,
Edinburgh, United Kingdom; Department of Psychiatry (ACH, PM), Wash-
ington University St. Louis, St. Louis, Missouri; Division of Applied Health
Sciences (LJH), University of Aberdeen, Aberdeen, United Kingdom;
Interfaculty Institute for Genetics and Functional Genomics (GH), University
of Greifswald, Greifswald; Max Planck Institute of Psychiatry (SK, SL, BM-
M), Munich, Germany; Mental Health Center Copenhagen (JK), Mental
Health Services in Capital Region, University of Copenhagen, Copenhagen,
Denmark; Institute of Neuroscience and Physiology (MLand), University of
Gothenburg, Gothenburg, Sweden; Department of Genetic Epidemiology in
Psychiatry (MLang, JSt), Central Institute of Mental Health, Medical Faculty
Mannheim/Heidelberg University, Mannheim, Germany; Department of
Psychiatry and Behavioral Sciences (DFL), Stanford University, Stanford,
California; Department of Psychiatry (YM, BWJHP, JHS), EMGO Institute for
Health and Care Research and Neuroscience Campus Amsterdam, Vrije
Universiteit Medical Center, Amsterdam, The Netherlands; Psychosis
Research Unit (OM), Aarhus University Hospital, Risskov, Denmark; Munich
Cluster for Systems Neurology (BM-M), Munich, Germany; Institute of
Translational Medicine (BM-M), University of Liverpool, Liverpool, United
Kingdom; Institute of Health and Biomedical Innovation (DRN), Queensland
University of Technology, Brisbane, Queensland, Australia; Therapeia (HO),
Reykjavik, Iceland; Institute of Cardiovascular and Medical Sciences (SP),
University of Glasgow, Glasgow, United Kingdom; Charles E. Schmidt
College of Medicine (MLP), Florida Atlantic University, Boca Raton, Florida;
Department of Psychiatry (JBP), University of Iowa Carver College of
Medicine, Iowa City, Iowa; Centro de Investigación Biomédica en Red de
Salud Mental–Universidad de Granada e Instituto de Investigación Bio-
sanitaria ibs (MR), Hospitales Universitarios de Granada/Universidad de
Granada, Granada, Spain; Division of Cancer Epidemiology and Genetics
(JSi), National Cancer Institute, National Institutes of Health, Bethesda,
Maryland; Department of Psychiatry (SIS), Group Health, Seattle, Wash-
ington; Faculty of Medicine, University of Iceland (ES); Department of
Psychiatry (ES), Landspitali University Hospital, Reykjavik, Iceland; Division
of Population Health Sciences (BHS), University of Dundee, Dundee,
United Kingdom; Department of Genetics (PFS), University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina; and College of
Physicians and Surgeons and the Mailman School of Public Health
(MMW), Columbia University and New York State Psychiatric Institute,
New York, New York.
See the Supplement for full lists of CONVERGE authors, CARDIoGRAM
authors, and GERAD1 investigators.
RAP and KET contributed equally to this work.
Address correspondence to Cathryn M. Lewis, Ph.D., Institute of
Psychiatry, Psychology and Neuroscience, King’s College London, London
SE5 8AF, United Kingdom; E-mail: cathryn.lewis@kcl.ac.uk.
Received Dec 1, 2015; revised Mar 26, 2016; accepted May 5, 2016.
Supplementary material cited in this article is available online at http://
dx.doi.org/10.1016/j.biopsych.2016.05.010.
REFERENCES
1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR,
et al. (2003): The epidemiology of major depressive disorder: Results
from the National Comorbidity Survey Replication (NCS-R). JAMA-
289:3095–3105.
2. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al.
(1999): Recurrence after recovery from major depressive disorder during
15 years of observational follow-up. Am J Psychiatry 156:1000–1006.Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 9
Genomic Analysis of Age at Onset in Depression
Biological
Psychiatry3. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al.
(2012): Years lived with disability (YLDs) for 1160 sequelae of 289
diseases and injuries 1990–2010: A systematic analysis for the Global
Burden of Disease Study 2010. Lancet 380:2163–2196.
4. American Psychiatric Association (1994): Diagnostic and Statistical
Manual of Mental Disorders, 4th ed. Washington, DC: American
Psychiatric Association.
5. Angst F, Stassen HH, Clayton PJ, Angst J (2002): Mortality of patients
with mood disorders: follow-up over 34–38 years. J Affect Disord 68:
167–181.
6. Barth J, Schumacher M, Herrmann-Lingen C (2004): Depression
as a risk factor for mortality in patients with coronary heart disease:
A meta-analysis. Psychosom Med 66:802–813.
7. Satin JR, Linden W, Phillips MJ (2009): Depression as a predictor of
disease progression and mortality in cancer patients: A meta-analysis.
Cancer 115:5349–5361.
8. Sullivan PF, Neale MC, Kendler KS (2000): Genetic epidemiology of
major depression: Review and meta-analysis. Am J Psychiatry 157:
1552–1562.
9. Major Depressive Disorder Working Group of the Psychiatric Gwas
Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman
MM, et al. (2013): A mega-analysis of genome-wide association
studies for major depressive disorder. Mol Psychiatry 18:497–511.
10. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS)
Consortium (2011): Genome-wide association study identiﬁes ﬁve
new schizophrenia loci. Nat Genet 43:969–976.
11. Psychiatric GWAS Consortium Bipolar Disorder Working Group
(2011): Large-scale genome-wide association analysis of bipolar
disorder identiﬁes a new susceptibility locus near ODZ4. Nat Genet
43:977–983.
12. Gillum LA, Gouveia C, Dorsey ER, Pletcher M, Mathers CD, Mcculloch
CE, Johnston SC (2011): NIH disease funding levels and burden of
disease. PLoS One 6:e16837.
13. Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Raue P, Friedman
SJ, Meyers BS (2001): Perceived stigma as a predictor of treatment
discontinuation in young and older outpatients with depression. Am J
Psychiatry 158:479–481.
14. Weissman MM, Wickramaratne P, Merikangas KR, Leckman JF,
Prusoff BA, Caruso KA, et al. (1984): Onset of major depression in
early adulthood: Increased familial loading and speciﬁcity. Arch Gen
Psychiatry 41:1136–1143.
15. Nierenberg AA, Trivedi MH, Fava M, Biggs MM, Shores-Wilson K,
Wisniewski SR, et al. (2007): Family history of mood disorder and
characteristics of major depressive disorder: A STAR*D (sequenced treat-
ment alternatives to relieve depression) study. J Psychiatr Res 41:214–221.
16. Tozzi F, Prokopenko I, Perry JD, Kennedy JL, McCarthy AD, Holsboer
F, et al. (2008): Family history of depression is associated with
younger age of onset in patients with recurrent depression. Psychol
Med 38:641–649.
17. Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, et al.
(1998): A registry-based twin study of depression in men. Arch Gen
Psychiatry 55:468–472.
18. Yang F, Li Y, Xie D, Shao C, Ren J, Wu W, et al. (2011): Age at onset of
major depressive disorder in Han Chinese women: Relationship with
clinical features and family history. J Affect Disord 135:89–94.
19. Wickramaratne PJ, Weissman MM (1998): Onset of psychopathology
in offspring by developmental phase and parental depression. J Am
Acad Child Adolesc Psychiatry 37, 933–942.
20. Kendler KS, Gatz M, Gardner CO, Pedersen NL (2005): Age at onset
and familial risk for major depression in a Swedish national twin
sample. Psychol Med 35:1573–1579.
21. Gillespie NA, Kirk KM, Evans DM, Heath AC, Hickie IB, Martin NG
(2004): Do the genetic or environmental determinants of anxiety and
depression change with age? A longitudinal study of Australian twins.
Twin Res 7:39–53.
22. Nivard MG, Dolan CV, Kendler KS, Kan KJ, Willemsen G, Van
Beijsterveldt CE, et al. (2015): Stability in symptoms of anxiety and
depression as a function of genotype and environment: a longitudinal
twin study from ages 3 to 63 years. Psychol Med 45:1039–1049.10 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal23. Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer
R, et al. (2010): Genome-wide association-, replication-, and neuro-
imaging study implicates HOMER1 in the etiology of major depres-
sion. Biol Psychiatry 68:578–585.
24. Sullivan PF, De Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt
T, et al. (2009): Genome-wide association for major depressive
disorder: a possible role for the presynaptic protein piccolo. Mol
Psychiatry 14:359–375.
25. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner
WA, et al. (2011): Genome-wide association study of recurrent early-
onset major depressive disorder. Mol Psychiatry 16:193–201.
26. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ,
et al. (2010): Genome-wide association study of recurrent major
depressive disorder in two European case-control cohorts. Mol
Psychiatry 15:589–601.
27. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD,
Nyholt DR, et al. (2012): Genome-wide association study of major
depressive disorder: new results, meta-analysis, and lessons learned.
Mol Psychiatry 17:36–48.
28. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al.
(2011): Novel loci for major depression identiﬁed by genome-wide
association study of Sequenced Treatment Alternatives to Relieve Depres-
sion and meta-analysis of three studies. Mol Psychiatry 16, 202–215.
29. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al.
(2010): Genome-wide association study of major recurrent depression
in the UK population. Am J Psychiatry 167:949–957.
30. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al.
(2009): A genomewide association study points to multiple loci that
predict antidepressant drug treatment outcome in depression. Arch
Gen Psychiatry 66:966–975.
31. Browning BL, Browning SR (2009): A uniﬁed approach to genotype
imputation and haplotype-phase inference for large data sets of trios
and unrelated individuals. Am J Hum Genet 84:210–223.
32. International HapMap 3 Consortium, Altshuler DM, Gibbs RA, Pelto-
nen L, Altshuler DM, Gibbs RA, et al. (2010): Integrating common and
rare genetic variation in diverse human populations. Nature 467:
52–58.
33. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D,
et al. (2007): PLINK: A tool set for whole-genome association and
population-based linkage analyses. Am J Hum Genet 81:559–575.
34. Macgregor S, Craddock N, Holmans PA (2006): ): Use of phenotypic
covariates in association analysis by sequential addition of cases. Eur
J Hum Genet 14:529–534.
35. Lichtenstein P, Sullivan PF, Cnattingius S, Gatz M, Johansson S,
Carlstrom E, et al. (2006): The Swedish Twin Registry in the third
millennium: An update. Twin Res Human Genet 9:875–882.
36. Preisig M, Waeber G, Vollenweider P, Bovet P, Rothen S, Vandeleur C,
et al. (2009): The PsyCoLaus study: methodology and characteristics
of the sample of a population-based survey on psychiatric disorders
and their association with genetic and cardiovascular risk factors.
BMC Psychiatry 9:9.
37. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, et al.
(2011): Cohort proﬁle: The study of health in Pomerania. Int J
Epidemiol 40:294–307.
38. Baune BT, Konrad C, Grotegerd D, Suslow T, Ohrmann P, Bauer J,
et al. (2012): Tumor necrosis factor gene variation predicts hippo-
campus volume in healthy individuals. Biol Psychiatry 72:655–662.
39. Grosse L, Carvalho LA, Wijkhuijs AJ, Bellingrath S, Ruland T, Ambree
O, et al. (2015): Clinical characteristics of inﬂammation-associated
depression: Monocyte gene expression is age-related in major
depressive disorder. Brain Behav Immun 44:48–56.
40. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, et al.
(2010): Genome-wide pharmacogenetics of antidepressant response
in the GENDEP project. Am J Psychiatry 167:555–564.
41. Krogh J, Petersen L, Timmermann M, Saltin B, Nordentoft M (2007):
Design paper: The DEMO trial: A randomized, parallel-group,
observer-blinded clinical trial of aerobic versus non-aerobic versus
relaxation training for patients with light to moderate depression.
Contemp Clin Trials 28:79–89.
Genomic Analysis of Age at Onset in Depression
Biological
Psychiatry42. Elfving B, Buttenschon HN, Foldager L, Poulsen PH, Andersen JH,
Grynderup MB, et al. (2012): Depression, the Val66Met polymorphism,
age, and gender inﬂuence the serum BDNF level. J Psychiatr Res 46:
1118–1125.
43. Yang F, Zhao H, Wang Z, Tao D, Xiao X, Niu Q, et al. (2014): Age at
onset of recurrent major depression in Han Chinese women: A
replication study. J Affect Disord 157:72–79.
44. CONVERGE Consortium (2015): Sparse whole-genome sequencing
identiﬁes two loci for major depressive disorder. Nature 523:588–591.
45. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM,
et al. (2013): Cohort proﬁle: Generation Scotland: Scottish Fam-
ily Health Study (GS:SFHS): The study, its participants and their potential
for genetic research on health and illness. Int J Epidemiol 42:689–700.
46. Willer CJ, Li Y, Abecasis GR (2010): METAL: Fast and efﬁcient meta-
analysis of genomewide association scans. Bioinformatics 26:2190–2191.
47. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone
JL, Visscher PM, O’Donovan MC, et al. (2009): Common polygenic
variation contributes to risk of schizophrenia and bipolar disorder.
Nature 460:748–752.
48. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere
ML, et al. (2009): Genome-wide association study identiﬁes variants at
CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41:
1088–1093.
49. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H,
et al. (2011): Large-scale association analysis identiﬁes 13 new
susceptibility loci for coronary artery disease. Nat Genet 43:333–338.B50. Cross-Disorder Group of the Psychiatric Genomics Consortium
(2013): Identiﬁcation of risk loci with shared effects on ﬁve major
psychiatric disorders: A genome-wide analysis. Lancet 381:
1371–1379.
51. Taylor WD, Aizenstein HJ, Alexopoulos GS (2013): The vascular
depression hypothesis: Mechanisms linking vascular disease with
depression. Mol Psychiatry 18:963–974.
52. Starkstein SE, Jorge R, Mizrahi R, Robinson RG (2005): The construct
of minor and major depression in Alzheimer’s disease. Am J Psychia-
try 162:2086–2093.
53. GTEx Consortium (2013): The Genotype-Tissue Expression (GTEx)
project. Nat Genet 45:580–585.
54. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. (2011):
Spatio-temporal transcriptome of the human brain. Nature 478:
483–489.
55. Kim-Cohen J, Caspi A, Mofﬁtt TE, Harrington H, Milne BJ, Poulton R
(2003): Prior juvenile diagnoses in adults with mental disorder:
Developmental follow-back of a prospective-longitudinal cohort. Arch
Gen Psychiatry 60:709–717.
56. Traylor M, Markus H, Lewis CM (2015): Homogeneous case sub-
groups increase power in genetic association studies. Eur J Human
Genet 23:863–869.
57. Zaitlen N, Lindstrom S, Pasaniuc B, Cornelis M, Genovese G,
Pollack S, et al. (2012): Informed conditioning on clinical covariates
increases power in case-control association studies. PLoS Genet 8:
e1003032.iological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 11
